Induced pluripotent stem cell-derived CAR-NK cell products such as FT596 eliminate the harvesting, initial shipping, and patient-specific manufacturing as it is off-the-shelf and is available ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as monotherapy and in combination with rituximab among patients with B-cell ...

Induced pluripotent stem cell-derived CAR-NK cell products such as FT596 eliminate the harvesting, initial shipping, and patient-specific manufacturing as it is off-the-shelf and is available ...

The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen ...

This is especially problematic in cases of blocked blood vessels, which can repeatedly starve large areas of the heart of ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.

This successful proof-of-concept study demonstrated massive T cell infiltration ... T and CAR-NK cell therapies in the future. ERNA-101 is a cell therapy that utilizes induced pluripotent stem ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular immunotherapies less expensive and more accessible to ...